A citation-based method for searching scientific literature

Jennifer H Lingler, Meryl A Butters, Amanda L Gentry, Lu Hu, Amanda E Hunsaker, William E Klunk, Meghan K Mattos, Lisa S Parker, J Scott Roberts, Richard Schulz. J Alzheimers Dis 2016
Times Cited: 22







List of co-cited articles
122 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish. Alzheimers Res Ther 2015
50
59

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Yen Ying Lim, Paul Maruff, Christine Getter, Peter J Snyder. Alzheimers Dement 2016
35
54

Disclosure of amyloid imaging results to research participants: has the time come?
Jennifer H Lingler, William E Klunk. Alzheimers Dement 2013
29
45

Safety of disclosing amyloid status in cognitively normal older adults.
Jeffrey M Burns, David K Johnson, Edward P Liebmann, Rebecca J Bothwell, Jill K Morris, Eric D Vidoni. Alzheimers Dement 2017
36
45

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. Alzheimers Dement 2013
279
40

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Marilyn S Albert, Steven T DeKosky, Dennis Dickson, Bruno Dubois, Howard H Feldman, Nick C Fox, Anthony Gamst, David M Holtzman, William J Jagust, Ronald C Petersen,[...]. Alzheimers Dement 2011
40

Patient and caregiver reactions to clinical amyloid imaging.
Joshua D Grill, Chelsea G Cox, Sarah Kremen, Mario F Mendez, Edmond Teng, Jill Shapira, John M Ringman, Liana G Apostolova. Alzheimers Dement 2017
19
47

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.
J Scott Roberts, Laura B Dunn, Gil D Rabinovici. Neurodegener Dis Manag 2013
31
40

Communicating mild cognitive impairment diagnoses with and without amyloid imaging.
Joshua D Grill, Liana G Apostolova, Szofia Bullain, Jeffrey M Burns, Chelsea G Cox, Malcolm Dick, Dean Hartley, Claudia Kawas, Sarah Kremen, Jennifer Lingler,[...]. Alzheimers Res Ther 2017
30
40

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Jessica Mozersky, Pamela Sankar, Kristin Harkins, Sara Hachey, Jason Karlawish. JAMA Neurol 2018
30
40

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine,[...]. Alzheimers Dement 2011
36

Disclosure of APOE genotype for risk of Alzheimer's disease.
Robert C Green, J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Tamsen Brown, Susan LaRusse Eckert, Melissa Butson, A Dessa Sadovnick, Kimberly A Quaid,[...]. N Engl J Med 2009
317
36

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.
Michael M Witte, Norman L Foster, Adam S Fleisher, Monique M Williams, Kimberly Quaid, Michael Wasserman, Gail Hunt, J Scott Roberts, Gil D Rabinovici, James L Levenson,[...]. Alzheimers Dement (Amst) 2015
24
31

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.
Jonathan Gooblar, Catherine M Roe, Natalie J Selsor, Matthew J Gabel, John C Morris. JAMA Neurol 2015
20
35

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Clifford R Jack, David A Bennett, Kaj Blennow, Maria C Carrillo, Billy Dunn, Samantha Budd Haeberlein, David M Holtzman, William Jagust, Frank Jessen, Jason Karlawish,[...]. Alzheimers Dement 2018
31

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure.
B R Ott, M A Pelosi, G Tremont, P J Snyder. Alzheimers Dement (N Y) 2016
15
40

Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
S A S A Bemelmans, K Tromp, E M Bunnik, R J Milne, S Badger, C Brayne, M H Schermer, E Richard. Alzheimers Res Ther 2016
33
27


Should we disclose amyloid imaging results to cognitively normal individuals?
Joshua D Grill, David K Johnson, Jeffrey M Burns. Neurodegener Dis Manag 2013
23
22

Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
Stephanie J B Vos, Frans Verhey, Lutz Frölich, Johannes Kornhuber, Jens Wiltfang, Wolfgang Maier, Oliver Peters, Eckart Rüther, Flavio Nobili, Silvia Morbelli,[...]. Brain 2015
180
22

Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context.
Gwendolien Vanderschaeghe, Jolien Schaeverbeke, Rik Vandenberghe, Kris Dierickx. Neuroethics 2017
10
50

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.
José L Molinuevo, Jordi Cami, Xavier Carné, Maria C Carrillo, Jean Georges, Maria B Isaac, Zaven Khachaturian, Scott Y H Kim, John C Morris, Florence Pasquier,[...]. Alzheimers Dement 2016
28
22

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
Gil D Rabinovici, Constantine Gatsonis, Charles Apgar, Kiran Chaudhary, Ilana Gareen, Lucy Hanna, James Hendrix, Bruce E Hillner, Cynthia Olson, Orit H Lesman-Segev,[...]. JAMA 2019
150
22

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Willemijn J Jansen, Rik Ossenkoppele, Dirk L Knol, Betty M Tijms, Philip Scheltens, Frans R J Verhey, Pieter Jelle Visser, Pauline Aalten, Dag Aarsland, Daniel Alcolea,[...]. JAMA 2015
748
18

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Saima Hedrick, Virginia Pappas,[...]. Alzheimers Dement 2013
58
18

Making sense of nonsense: experiences of mild cognitive impairment.
Renée L Beard, Tara M Neary. Sociol Health Illn 2013
53
18

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.
Sanna-Kaisa Herukka, Anja Hviid Simonsen, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi,[...]. Alzheimers Dement 2017
75
18

Dementia specialists and early adoption of amyloid imaging.
Eran P Klein, Jeffrey Kaye. J Alzheimers Dis 2013
12
33

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. J Nucl Med 2013
153
18

Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment.
Pieter Jelle Visser, Henrike Wolf, Giovanni Frisoni, Hermann-Josef Gertz. Biomark Med 2012
15
26


Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
Scott Y H Kim, Jason Karlawish, Benjamin E Berkman. Neurology 2015
28
18

The A4 study: stopping AD before symptoms begin?
Reisa A Sperling, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, Paul Aisen. Sci Transl Med 2014
422
18

Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
Gwendolien Vanderschaeghe, Jolien Schaeverbeke, Rose Bruffaerts, Rik Vandenberghe, Kris Dierickx. Alzheimers Res Ther 2017
13
30

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.
Arno de Wilde, Wiesje M van der Flier, Wiesje Pelkmans, Femke Bouwman, Jurre Verwer, Colin Groot, Marieke M van Buchem, Marissa Zwan, Rik Ossenkoppele, Maqsood Yaqub,[...]. JAMA Neurol 2018
53
18

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.
Arno de Wilde, Marieke M van Buchem, René H J Otten, Femke Bouwman, Andrew Stephens, Frederik Barkhof, Philip Scheltens, Wiesje M van der Flier. Alzheimers Res Ther 2018
19
21


Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E Klunk, Henry Engler, Agneta Nordberg, Yanming Wang, Gunnar Blomqvist, Daniel P Holt, Mats Bergström, Irina Savitcheva, Guo-feng Huang, Sergio Estrada,[...]. Ann Neurol 2004
13

Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment.
Vanessa Lawrence, James Pickett, Clive Ballard, Joanna Murray. Int J Geriatr Psychiatry 2014
22
13

Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care.
Liana G Apostolova, Janelle M Haider, Naira Goukasian, Gil D Rabinovici, Gael Chételat, John M Ringman, Sarah Kremen, Joshua D Grill, Lucas Restrepo, Mario F Mendez,[...]. Alzheimers Dement (Amst) 2016
23
13

Living With Ambiguity: A Metasynthesis of Qualitative Research on Mild Cognitive Impairment.
Tim Gomersall, Arlene Astell, Louise Nygård, Andrew Sixsmith, Alex Mihailidis, Amy Hwang. Gerontologist 2015
26
13

Using AD biomarker research results for clinical care: a survey of ADNI investigators.
Melanie B Shulman, Kristin Harkins, Robert C Green, Jason Karlawish. Neurology 2013
27
13

Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues.
Antoine Leuzy, Eduardo Rigon Zimmer, Kerstin Heurling, Pedro Rosa-Neto, Serge Gauthier. Amyloid 2014
23
13

Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease.
Elizabeth M Wikler, Robert J Blendon, John M Benson. Alzheimers Res Ther 2013
27
13

Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study.
J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Robert C Green. J Geriatr Psychiatry Neurol 2005
93
13

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Harald Hampel, José Luis Molinuevo, Kaj Blennow, Steven T DeKosky, Serge Gauthier, Dennis Selkoe, Randall Bateman,[...]. Lancet Neurol 2014
13

Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk.
Holly C Gooding, Erin L Linnenbringer, Jeffrey Burack, J Scott Roberts, Robert C Green, Barbara B Biesecker. Patient Educ Couns 2006
43
13

Public perceptions of presymptomatic testing for Alzheimer disease.
Richard J Caselli, Jessica Langbaum, Gary E Marchant, Rachel A Lindor, Katherine S Hunt, Bruce R Henslin, Amylou C Dueck, Jason S Robert. Mayo Clin Proc 2014
31
13

Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
Joshua D Grill, Yan Zhou, David Elashoff, Jason Karlawish. Neurobiol Aging 2016
20
15

18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Gabriel Martínez, Robin Wm Vernooij, Paulina Fuentes Padilla, Javier Zamora, Leon Flicker, Xavier Bonfill Cosp. Cochrane Database Syst Rev 2017
20
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.